Buggy, Joseph J.

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Byrd, J. C., Furman, R. R., Coutre, S. E., Flinn, I. W., Burger, J. A., Blum, K. A., Grant, B., Sharman, J. P., Coleman, M., Wierda, W. G., et al. (2013) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 2,270

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

Wang, M. L., Rule, S., Martin, P., Goy, A., Auer, R., Kahl, B. S., Jurczak, W., Advani, R. H., Romaguera, J. E., Williams, M. E., et al. (2013) · New England Journal of Medicine

Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research

Cited by 1,685

The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy

Honigberg, L. A., Smith, A. M., Sirisawad, M., Verner, E., Loury, D., Chang, B., Li, S., Pan, Z., Thamm, D. H., Miller, R. A., et al. (2010) · Proceedings of the National Academy of Sciences

T-cell and B-cell ImmunologyLymphoma Diagnosis and Treatment

Cited by 1,561

Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib

Woyach, J. A., Furman, R. R., Liu, T.-M., Ozer, H. G., Zapatka, M., Ruppert, A. S., Xue, L., Li, D. H.-H., Steggerda, S. M., Versele, M., et al. (2014) · New England Journal of Medicine

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 1,275

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies

Advani, R. H., Buggy, J. J., Sharman, J. P., Smith, S. M., Boyd, T. E., Grant, B., Kolibaba, K. S., Furman, R. R., Rodriguez, S., Chang, B. Y., et al. (2013) · Journal of Clinical Oncology

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 1,128

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

Dubovsky, J. A., Beckwith, K. A., Natarajan, G., Woyach, J. A., Jaglowski, S., Zhong, Y., Hessler, J. D., Liu, T.-M., Chang, B. Y., Larkin, K. M., et al. (2013) · Blood

Chronic Lymphocytic Leukemia ResearchT-cell and B-cell Immunology

Cited by 810

Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765

Herman, S. E. M., Gordon, A. L., Hertlein, E., Ramanunni, A., Zhang, X., Jaglowski, S., Flynn, J., Jones, J., Blum, K. A., Buggy, J. J., et al. (2011) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 807

Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases

Somoza, J. R., Skene, R. J., Katz, B. A., Mol, C., Ho, J. D., Jennings, A. J., Luong, C., Arvai, A., Buggy, J. J., Chi, E., et al. (2004) · Structure

Histone Deacetylase Inhibitors ResearchEnzyme Structure and Function

Cited by 710

The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo

Ponader, S., Chen, S.-S., Buggy, J. J., Balakrishnan, K., Gandhi, V., Wierda, W. G., Keating, M. J., O'Brien, S., Chiorazzi, N., & Burger, J. A. (2012) · Blood

Chronic Lymphocytic Leukemia ResearchLymphoma Diagnosis and Treatment

Cited by 640

A novel histone deacetylase 8 (HDAC8)-specific inhibitor PCI-34051 induces apoptosis in T-cell lymphomas

Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia

Histone Deacetylase Inhibitors ResearchCell death mechanisms and regulation

Cited by 458

Cloning and characterization of a novel human histone deacetylase, HDAC8

BUGGY, J. J., SIDERIS, M. L., MAK, P., LORIMER, D. D., MCINTOSH, B., & CLARK, J. M. (2000) · Biochemical Journal

Histone Deacetylase Inhibitors ResearchGenomics and Chromatin Dynamics

Cited by 197

CRA-024781: a novel synthetic inhibitor of histone deacetylase enzymes with antitumor activity in vitro and in vivo

Buggy, J. J., Cao, Z. A., Bass, K. E., Verner, E., Balasubramanian, S., Liu, L., Schultz, B. E., Young, P. R., & Dalrymple, S. A. (2006) · Molecular Cancer Therapeutics

Histone Deacetylase Inhibitors ResearchEpigenetics and DNA Methylation

Cited by 127

Data from PCI-24781 Induces Caspase and Reactive Oxygen Species–Dependent Apoptosis Through NF-κB Mechanisms and Is Synergistic with Bortezomib in Lymphoma Cells

Bhalla, S., Balasubramanian, S., David, K., Sirisawad, M., Buggy, J., Mauro, L., Prachand, S., Miller, R., Gordon, L. I., & Evens, A. M. (2023)

Histone Deacetylase Inhibitors ResearchCell death mechanisms and regulation

Cited by 1